Hepatitis B core protein inhibitor, ABI-H0731, produces promising results in Phase 2a studies
ILC 2019: Interim data from two Phase 2a studies of ABI-H0731 suggest good tolerability and enhanced antiviral efficacy in combination with standard-of-care in chronic hepatitis B infection 13 April 2019,…
Calmangafodipir may reduce liver injury after paracetamol overdose: final results from the POP trial
ILC 2019: Phase 1 study demonstrates that superoxide dismutase mimetic, calmangafodipir, is well tolerated and may reduce liver injury after paracetamol overdose 12 April 2019, Vienna, Austria EASL (EUROPEAN ASSOCIATION…
Glecaprevir/pibrentasvir (G/P) is effective and well tolerated in large ‘real-world’ studies in individuals with hepatitis C virus (HCV) infection
ILC 2019: German and US studies confirm the efficacy and safety of G/P in a broad range of individuals with HCV infection and other comorbidities, showing improvements in mental and…
Nonalcoholic fatty liver disease found in large numbers of teenagers and young adults: is a public health crisis looming?
ILC 2019: UK population-based study finds large numbers of young adults have nonalcoholic fatty liver disease (NAFLD) and many of these already have fibrosis 12 April 2019, Vienna, Austria EASL…
MSDC-0602K shows potential for improving markers of liver disease in individuals with nonalcoholic steatohepatitis (NASH)
ILC 2019: Second-generation thiazolidinedione, MSDC-0602K may significantly improve liver enzymes, fibrosis, and glycaemic markers with minimal adverse events, according to a Phase 2b study 12 April 2019, Vienna, Austria EASL…